Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

CTLA-4 Control over Foxp3 + Regulatory T Cell Function

Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766

Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation

Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206

Plat-E: an efficient and stable system for transient packaging of retroviruses

MORITA, S., Kojima, T., & Kitamura, T. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301206 · Cited by 1,660

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967

CD28 and CTLA-4 coreceptor expression and signal transduction

Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898

Foxp3 + natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation

Onishi, Y., Fehervari, Z. T., Yamaguchi, T., & Sakaguchi, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711106105 · Cited by 754

B cells acquire antigen from target cells after synapse formation

Batista, F. D., Iber, D., & Neuberger, M. S. (2001) · Nature · doi:10.1038/35078099 · Cited by 629

A MOLECULAR PERSPECTIVE OF CTLA-4 FUNCTION

Teft, W. A., Kirchhof, M. G., & Madrenas, J. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090535 · Cited by 526

Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management

Tang, L., Wang, J., Lin, N., Zhou, Y., He, W., Liu, J., & Ma, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.800879 · Cited by 139

Combination of Radiotherapy and Immune Checkpoint Inhibitors

Pilones, K. A., Vanpouille‐Box, C., & Demaria, S. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.004 · Cited by 140

Immunotherapy earns its spot in the ranks of cancer therapy

Pardoll, D. M., & Drake, C. G. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20112275 · Cited by 134

Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types

Oyewole-Said, D., Konduri, V., Vazquez‐Perez, J., Weldon, S. A., Levitt, J. M., & Decker, W. K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.608024 · Cited by 144

Treg therapy in transplantation: a general overview

Romano, M., Tung, S. L., Smyth, L. A., & Lombardi, G. (2016) · Transplant International · doi:10.1111/tri.12909 · Cited by 137

The soluble isoform of CTLA‐4 as a regulator of T‐cell responses

Ward, F. J., Dahal, L. N., Wijesekera, S. K., Abdul-Jawad, S., Kaewarpai, T., Xu, H., Vickers, M. A., & Barker, R. N. (2013) · European Journal of Immunology · doi:10.1002/eji.201242529 · Cited by 133

Recent Advances and Challenges in Cancer Immunotherapy

Peterson, C. M., Denlinger, N., & Yang, Y. (2022) · Cancers · doi:10.3390/cancers14163972 · Cited by 140

Orchestrating immune check-point blockade for cancer immunotherapy in combinations

Perez‐Gracia, J. L., Labiano, S., Rodriguez-Ruiz, M. E., Sanmamed, M. F., & Melero, I. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.002 · Cited by 131

CD47-dependent immunomodulatory and angiogenic activities of extracellular vesicles produced by T cells

Kaur, S., SINGH, S. P., ELKAHLOUN, A. G., Wu, W., Abu-Asab, M. S., & Roberts, D. D. (2014) · Matrix Biology · doi:10.1016/j.matbio.2014.05.007 · Cited by 133

Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potential

Spitz, C., Winkels, H., Bürger, C., Weber, C., Lutgens, E., Hansson, G. K., & Gerdes, N. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2080-2 · Cited by 134

Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies

Liu, Y., Guo, J., & Huang, L. (2020) · Theranostics · doi:10.7150/thno.42998 · Cited by 129

Natural killer (NK)–dendritic cell interactions generate MHC class II-dressed NK cells that regulate CD4 + T cells

NAKAYAMA, M., Takeda, K., Kawano, M., Takai, T., Ishii, N., & Ogasawara, K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110584108 · Cited by 137

Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors

Dutta, S., Ganguly, A., Chatterjee, K., Spada, S., & Mukherjee, S. (2023) · Biology · doi:10.3390/biology12020218 · Cited by 137

Tumor microenvironment (TME)-driven immune suppression in B cell malignancy

Nicholas, N. S., Apollonio, B., & Ramsay, A. G. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.11.003 · Cited by 131

CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination

Ahrends, T., Bąbała, N., Xiao, Y., Yagita∥, H., van Eenennaam, H., & Borst, J. G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3130 · Cited by 129

Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets

Tsai, H.-F., & Hsu, P. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0341-0 · Cited by 134

The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy

Mpakali, A., & Stratikos, E. (2021) · Cancers · doi:10.3390/cancers13010134 · Cited by 130

Targeting TFH cells in human diseases and vaccination: rationale and practice

Yu, D., Walker, L. S. K., Liu, Z., Linterman, M. A., & Li, Z. (2022) · Nature Immunology · doi:10.1038/s41590-022-01253-8 · Cited by 125

Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases

Naran, K., Nundalall, T., Chetty, S., & Barth, S. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03158 · Cited by 128

Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression

McBride, M. A., Patil, T. K., Bohannon, J. K., Hernandez, A., Sherwood, E. R., & Patil, N. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.624272 · Cited by 127

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

Vardhana, S. A., & Younes, A. (2016) · Haematologica · doi:10.3324/haematol.2015.132761 · Cited by 124

Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer

Eckert, F., Schilbach, K., Klumpp, L., Bardoscia, L., Sezgın, E., Schwab, M. G., Zips, D., & Huber, S. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03018 · Cited by 124

Understanding the CD28/CTLA-4 (CD152) Pathway and Its Implications for Costimulatory Blockade

Gardner, D. H., Jeffery, L. E., & Sansom, D. M. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12834 · Cited by 121

Organ-Specific and Memory Treg Cells: Specificity, Development, Function, and Maintenance

Gratz, I. K., & Campbell, D. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00333 · Cited by 123

Tregs restrain dendritic cell autophagy to ameliorate autoimmunity

Alissafi, T., Banos, A., Boon, L., Sparwasser, T. D., Ghigo, A., Wing, K., Vassilopoulos, D., Boumpas, D. T., Chavakis, T., Cadwell, K., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92079 · Cited by 123

Immune checkpoint inhibitors in advanced non–small cell lung cancer

Assi, H. I., Kamphorst, A. O., Moukalled, N. M., & Ramalingam, S. S. (2017) · Cancer · doi:10.1002/cncr.31105 · Cited by 123

Immune checkpoints in cancer clinical trials

Sharon, E., STREICHER, H. Z., Goncalves, P. H., & Chen, H. X. (2014) · 癌症：英文版 · doi:10.5732/cjc.014.10122 · Cited by 121

Antigen-specific regulatory T-cell responses to intestinal microbiota

Russler-Germain, E. V., Rengarajan, S., & Hsieh, C.-S. (2017) · Mucosal Immunology · doi:10.1038/mi.2017.65 · Cited by 123

Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions

Zhang, C., Zhang, C., & Wang, H. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216182 · Cited by 125

Regulatory T Cells: Serious Contenders in the Promise for Immunological Tolerance in Transplantation

Safinia, N., Scottà, C., Vaikunthanathan, T., Lechler, R. I., & Lombardi, G. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00438 · Cited by 119

Vitamin D Actions on CD4+ T Cells in Autoimmune Disease

Hayes, C. E., Hubler, S. L., Moore, J. R., Barta, L. E., Praska, C. E., & Nashold, F. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00100 · Cited by 123

A Transendocytosis Model of CTLA-4 Function Predicts Its Suppressive Behavior on Regulatory T Cells

Hou, T. Z., Qureshi, O., Wang, C. J., Baker, J., Young, S. P., Walker, L. S. K., & Sansom, D. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401876 · Cited by 123

The Role of the PI3K Signaling Pathway in CD4+ T Cell Differentiation and Function

Han, J. M., Patterson, S. J., & Levings, M. K. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00245 · Cited by 120

Suppression of the immunologic response to peanut during immunotherapy is often transient

Gorelik, M., Narisety, S. D., Guerrerio, A. L., Chichester, K. L., Keet, C. A., Bieneman, A. P., Hamilton, R. G., Wood, R. A., Schroeder, J. T., & Frischmeyer‐Guerrerio, P. A. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.11.010 · Cited by 118

Immune evasion in acute myeloid leukemia: current concepts and future directions

Teague, R. M., & Kline, J. P. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-13 · Cited by 119

Overexpression of Cytotoxic T-Lymphocyte–Associated Antigen-4 Prevents Atherosclerosis in Mice

Matsumoto, T., Sasaki, N., Yamashita, T., Emoto, T., Kasahara, K., Mizoguchi, T., Hayashi, T., Yodoi, K., Kitano, N., Saito, T., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306848 · Cited by 118

Immune checkpoint blockade opens a new way to cancer immunotherapy

Sadreddini, S., Baradaran, B., Aghebati‐Maleki, A., Sadreddini, S., Shanehbandi, D., Fotouhi, A., & Maleki, L. A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27816 · Cited by 119

Signal pathways and precision therapy of small-cell lung cancer

Yuan, M., Zhao, Y., Arkenau, H., Lao, T., Chu, L., & Xu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01013-y · Cited by 117

Current Understanding of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Signaling in T-Cell Biology and Disease Therapy

Kim, G., & Choi, J. (2022) · Molecules and Cells · doi:10.14348/molcells.2022.2056 · Cited by 131

Immune checkpoint blockade immunotherapy to activate anti‐tumour T ‐cell immunity

Ramsay, A. G. (2013) · British Journal of Haematology · doi:10.1111/bjh.12380 · Cited by 123

Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications

Popp, I., Grosu, A., Niedermann, G., & Duda, D. G. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.07.013 · Cited by 118

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis

Kumar, P., Saini, S., & Prabhakar, B. S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.01.006 · Cited by 117

Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer

Lurje, I., Hammerich, L., & Tacke, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197378 · Cited by 118

Liver metastasis from colorectal cancer: pathogenetic development, immune landscape of the tumour microenvironment and therapeutic approaches

Wang, Y., Zhong, X., He, X., Hu, Z., Huang, H., Chen, J., Chen, K., Zhao, S., Wei, P., & Li, D. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02729-7 · Cited by 131

The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review

Abdul‐Rahman, T., Ghosh, S., Badar, S. M., Nazir, A., Bamigbade, G. B., Aji, N., Roy, P., kachani, H., Garg, N. K., Lawal, L., et al. (2024) · European journal of medical research · doi:10.1186/s40001-024-01711-z · Cited by 131

Regulatory T cells in the tumour microenvironment

Imianowski, C. J., Chen, Q., Workman, C. J., & Vignali, D. A. A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00832-9 · Cited by 144

Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity

Yano, H., Andrews, L. P., Workman, C. J., & Vignali, D. A. A. (2019) · Immunology · doi:10.1111/imm.13067 · Cited by 116

Imaging regulatory T cell dynamics and CTLA4-mediated suppression of T cell priming

Matheu, M. P., Othy, S., Greenberg, M. L., Dong, H., Schuijs, M. J., Deswarte, K., Hammad, H., Lambrecht, B. N., Parker, I., & Cahalan, M. D. (2015) · Nature Communications · doi:10.1038/ncomms7219 · Cited by 116

Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy

Zhu, Y., Yu, X., Thamphiwatana, S., Zheng, Y., & Pang, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.08.010 · Cited by 118

Regulatory T cell targeting in cancer: Emerging strategies in immunotherapy

Dees, S., Ganesan, R., Singh, S., & Grewal, I. S. (2020) · European Journal of Immunology · doi:10.1002/eji.202048992 · Cited by 116

Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy

Geels, S. N., Moshensky, A., Sousa, R. S., Murat, C., Bustos, M. A., Walker, B. L., Singh, R., Harbour, S. N., Gutierrez, G., Hwang, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.013 · Cited by 124

Therapeutic use of anti-CTLA-4 antibodies

Blank, C. U., & Enk, A. (2014) · International Immunology · doi:10.1093/intimm/dxu076 · Cited by 115

Regulatory T‐cells in systemic lupus erythematosus and rheumatoid arthritis

Chavele, K.-M., & Ehrenstein, M. R. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.07.043 · Cited by 114

Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy

Carlson, R. D., Flickinger, J. C., & Snook, A. E. (2020) · Toxins · doi:10.3390/toxins12040241 · Cited by 131

Tumour Immunogenicity, Antigen Presentation, and Immunological Barriers in Cancer Immunotherapy

Escors, D. (2014) · New Journal of Science · doi:10.1155/2014/734515 · Cited by 119

Noncoding RNA s and immune checkpoints—clinical implications as cancer therapeutics

Smolle, M. A., Calin, H. N., Pichler, M., & Călin, G. A. (2017) · FEBS Journal · doi:10.1111/febs.14030 · Cited by 114

Regulatory T Cells in Allergy and Asthma

Martín‐Orozco, E., Norte‐Muñoz, M., & Martínez-García, J. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00117 · Cited by 113

Gut microbiota-mediated immunomodulation in tumor

Liu, X., Chen, Y., Zhang, S., & Dong, L. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01983-x · Cited by 112

Interleukin-2 and regulatory T cells in rheumatic diseases

Kolios, A. G. A., Tsokos, G. C., & Klatzmann, D. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00707-x · Cited by 116

HGF/MET and the Immune System: Relevance for Cancer Immunotherapy

Papaccio, F., Della Corte, C. M., Viscardi, G., Di Liello, R., Esposito, G., Sparano, F., Ciardiello, F., & Morgillo, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113595 · Cited by 110

T follicular regulatory (Tfr) cells: Dissecting the complexity of Tfr‐cell compartments

Fonseca, V. R., Ribeiro, F., & Graça, L. (2019) · Immunological Reviews · doi:10.1111/imr.12739 · Cited by 111

The nature of activatory and tolerogenic dendritic cell-derived signal II

Bakdash, G., Sittig, S. P., van Dijk, T., Figdor, C. G., & de Vries, I. J. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00053 · Cited by 126

Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression

Yamaguchi, T., Kishi, A., Osaki, M., Morikawa, H., Martín, P. P., Wing, K., Saito, T., & Sakaguchi, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307185110 · Cited by 111

Update on Dendritic Cell-Induced Immunological and Clinical Tolerance

Obregon, C., Kumar, R., Pascual, M. A., Vassalli, G., & Golshayan, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01514 · Cited by 111

Antigen-Specific Regulatory T Cell Therapy in Autoimmune Diseases and Transplantation

Selck, C., & Dominguez‐Villar, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661875 · Cited by 109

Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications

Vuong, J. T., Stein-Merlob, A. F., Nayeri, A., Sallam, T., Neilan, T. G., & Yang, E. H. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.048 · Cited by 116

Signaling in Lymphocyte ActivationPreprint

Cantrell, D. A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018788 · Cited by 115

Immune synapse: conductor of orchestrated organelle movement

Martin-Cofreces, N. B., Baixauli, F., & Sánchez‐Madrid, F. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.09.005 · Cited by 108

Expanding Roles for CD4 T Cells and Their Subpopulations in Tumor Immunity and Therapy

Dobrzanski, M. J. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00063 · Cited by 116

Immune checkpoints in central nervous system autoimmunity

Joller, N., Peters, A., Anderson, A. C., & Kuchroo, V. K. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01136.x · Cited by 106

Crosstalk of pyroptosis and cytokine in the tumor microenvironment: from mechanisms to clinical implication

Wang, H., Wang, T., Yan, S., Tang, J., Zhang, Y., Wang, L., Xu, H., & Tu, C. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02183-9 · Cited by 122

Gastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management

Samaan, M. A., Pavlidis, P., Papa, S., Powell, N., & Irving, P. M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2018.14 · Cited by 100

CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer

Bengsch, F., Knoblock, D. M., Liu, A., McAllister, F. M., & Beatty, G. L. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2053-4 · Cited by 105

The Role of Trogocytosis in the Modulation of Immune Cell Functions

Miyake, K., & Karasuyama, H. (2021) · Cells · doi:10.3390/cells10051255 · Cited by 109

Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment

Lisi, L., Lacal, P. M., Martire, M., Navarra, P., & Graziani, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105997 · Cited by 106

Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations

Hou, T. Z., Verma, N., Wanders, J., Kennedy, A., Soskic, B., Janman, D., Halliday, N., Rowshanravan, B., Worth, A. J. J., Qasim, W., et al. (2017) · Blood · doi:10.1182/blood-2016-10-745174 · Cited by 104

Regulatory T Cells Selectively Control CD8+ T Cell Effector Pool Size via IL-2 Restriction

Kastenmüller, W., Gasteiger, G., Subramanian, N., Sparwasser, T. D., Busch, D. H., Belkaid, Y., Drexler, I., & Germain, R. N. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101649 · Cited by 99

NF-κB and Its Role in Checkpoint Control

Betzler, A. C., Theodoraki, M., Schuler, P. J., Döscher, J., Laban, S. A., Hoffmann, T. K., & Brunner, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113949 · Cited by 106

The Role of Immunotherapy in Pancreatic Cancer

Mukherji, R., Debnath, D., Hartley, M. L., & Noel, M. S. (2022) · Current Oncology · doi:10.3390/curroncol29100541 · Cited by 106

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways

Touchaei, A. Z., & Vahidi, S. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03293-6 · Cited by 102

Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma

Moy, J. D., Moskovitz, J. M., & Ferris, R. L. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.035 · Cited by 102

Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End

Datsi, A., & Sorg, R. V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.770390 · Cited by 105

Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells

Alissafi, T., Hatzioannou, A., Legaki, A. I., Varveri, A., & Verginis, P. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102310 · Cited by 98

Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges

Kunimasa, K., & Goto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020597 · Cited by 106

Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance

Géraud, A., Gougis, P., Vozy, A., Anquetil, C., Allenbach, Y., Romano, E., Funck‐Brentano, E., Moslehi, J. J., Johnson, D. B., & Salem, J. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022820-093805 · Cited by 97

Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy

Khan, M. S. I., Arooj, S., & Wang, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.651634 · Cited by 101

Mechanisms of immunological tolerance

Waldmann, H. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.05.019 · Cited by 98

Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans

Corse, E., & Allison, J. P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200695 · Cited by 97

Immunotherapy of cancers comes of age

Yousefi, H., Yuan, J. D., Keshavarz‐Fathi, M., Murphy, J. F., & Rezaei, N. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1366315 · Cited by 97

CD8 + T cell exhaustion in anti‐tumour immunity: The new insights for cancer immunotherapy

Huang, Y., Jia, A., Wang, Y., & Liu, G. (2022) · Immunology · doi:10.1111/imm.13588 · Cited by 96

Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy

Babamohamadi, M., Mohammadi, N., Faryadi, E., Haddadi, M., Merati, A., Ghobadinezhad, F., Amirian, R., Izadi, Z., & Hadjati, J. (2024) · Cell Death and Disease · doi:10.1038/s41419-023-06391-x · Cited by 104

Negative co-stimulation constrains T cell differentiation by imposing boundaries on possible cell states

Wei, S. C., Sharma, R., Anang, N.-A. A. S., Levine, J. H., Zhao, Y., Mancuso, J. J., Setty, M., Sharma, P., Wang, J., Pe’er, D., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.004 · Cited by 97

CD86 Is a Selective CD28 Ligand Supporting FoxP3+ Regulatory T Cell Homeostasis in the Presence of High Levels of CTLA‐4

Halliday, N., Williams, C., Kennedy, A., Waters, E., Pesenacker, A. M., Soskic, B., Hinze, C., Hou, T. Z., Rowshanravan, B., Janman, D., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600000 · Cited by 95

The Soluble CTLA-4 Splice Variant Protects From Type 1 Diabetes and Potentiates Regulatory T-Cell Function

Gerold, K. D., Zheng, P., Rainbow, D. B., Zernecke, A., Wicker, L. S., & Kissler, S. (2011) · Diabetes · doi:10.2337/db11-0130 · Cited by 98

Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting

Revilla, S. A., Kranenburg, O., & Coffer, P. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903564 · Cited by 104

Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance

Medler, T. R., Cotechini, T., & Coussens, L. M. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.07.008 · Cited by 97

Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy

Śledzińska, A., Menger, L., Bergerhoff, K. F., Peggs, K. S., & Quezada, S. A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.008 · Cited by 95

Role of dendritic cell maturity/costimulation for generation, homeostasis, and suppressive activity of regulatory T cells

Pletinckx, K. (2011) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00039 · Cited by 99

The application of nanotechnology in immune checkpoint blockade for cancer treatment

Deng, H., & Zhang, Z. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.026 · Cited by 95

Impaired function of dendritic cells within the tumor microenvironment

Xiao, Z., Wang, R., Wang, X., Yang, H., Dong, J.-M., He, X., Yang, Y., Guo, J., Cui, J., & Zhou, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213629 · Cited by 105

CTLA-4-mediated trans-endocytosis in the control of T cell co-stimulation

Ovcinnikovs, V. (2018) · UCL Discovery (University College London)

Investigating transendocytosis mediated by CTLA4

Nguyen, L. (2023) · UNSWorks (University of New South Wales, Sydney, Australia) · doi:10.26190/unsworks/24962

CTLA4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis

Xu, X., Dennett, P., Zhang, J., Sherrard, A., Zhao, Y., Masubuchi, T., Bui, J. D., Chen, X., & Hui, E. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221391 · Cited by 56

Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation

Kennedy, A., Waters, E., Rowshanravan, B., Hinze, C., Williams, C., Janman, D., Fox, T. A., Booth, C., Pesenacker, A. M., Halliday, N., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01289-w · Cited by 227

Molecular and Cellular Functions of CTLA-4

Coillie, S. V., Wiernicki, B., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_2 · Cited by 259